Research Progress of ALK Activation Pattern Changes and Targeted Therapy
in Advanced Lung Cancer.
10.3779/j.issn.1009-3419.2024.102.45
- Author:
Aojiao WEI
1
;
Bo JIANG
2
;
Yurong HUANG
1
;
Mengyun LIU
1
;
Jing YAN
1
;
Yuanyuan ZHAO
1
;
Wenjie HE
2
Author Information
1. Kunming Medical University, Kunming 650500, China.
2. Department of Geriatric Oncology, The Third Affiliated Hospital of
Kunming Medical University, Kunming 650118, China.
- Publication Type:English Abstract
- Keywords:
Anaplastic lymphoma kinase;
Anaplastic lymphoma kinase activation patten change;
Anaplastic lymphoma kinase inhibitors;
Lung neoplasms;
Targeted therapy
- MeSH:
Humans;
Lung Neoplasms/pathology*;
Anaplastic Lymphoma Kinase;
Molecular Targeted Therapy;
Receptor Protein-Tyrosine Kinases/antagonists & inhibitors*;
Protein Kinase Inhibitors/therapeutic use*
- From:
Chinese Journal of Lung Cancer
2024;27(12):940-946
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the most common cancer in China and even in the world, and it is also the main cause of cancer death. Patients with anaplastic lymphoma kinase (ALK) gene alterations have the opportunity to receive molecularly targeted therapies. The inhibitors of anaplastic lymphoma kinase, such as ALK-tyrosine kinase inhibitors (ALK-TKIs) significantly prolong the survival of patients. ALK gene variant types include point mutation, amplification, fusion/rearrangement, and ALK fusion is more common than other types. However, the effect of different types of gene changes in molecular targeted therapy is different. Therefore, this paper introduced the relevant contents of different variants of ALK gene, focused on the research progress of targeted therapy, and proposed the future development direction.
.
